Figure 3.

Effect of chronic low‐dose aspirin treatment on early stages in AOM/DSS‐induced tumorigenesis. (A and B) Assessment of apoptosis by cleaved caspase‐3 staining (A) and TUNEL assay (B) of colons from control and aspirin‐treated mice (n = 4‐6/group) 4 h after AOM administration. (C) Schematic representation of the AOM/DSS protocol and aspirin treatment regimens for assessment of aberrant crypt formation. (D) Number of aberrant crypt foci and (E) plasma TXB₂ concentration of mice (n = 6/group) after 4 wks of aspirin administration. (F) Schematic representation of the 12‐week AOM/DSS protocol in combination with different aspirin treatment regimens. (G) Tumor number, (H) tumor size, and (I) plasma TXB₂ concentration of mice (n = 6/group) following 12 wks of aspirin administration. *P < .05, **P < .01, ***P < .001 by unpaired Student's t test